Universal CAR-T redirection by membrane-inserted ligands

Technology
Conceptual
University
Scouted & summarized by Halo AI

Universal CAR-T redirection by membrane-inserted ligands is a research-stage, tumor-agnostic strategy for treating solid tumors. By intratumorally injecting an amphiphile-ligand conjugate, researchers can label tumor cells with a specific tag, enabling recognition and destruction by engineered CAR T cells. This approach overcomes challenges related to antigen heterogeneity and promotes systemic antitumor immunity by priming endogenous T cells, offering a modular platform for potential future adoptive cell therapies.

Overview

Universal CAR-T redirection by membrane-inserted ligands is a research-stage strategy developed by the University of Pennsylvania to overcome the challenges of targeting solid tumors with chimeric antigen receptor (CAR) T cell therapy. Traditional CAR-T therapies often struggle with solid tumors due to the heterogeneous expression of tumor antigens and the risk of off-target toxicity in healthy tissues. This approach uses a tumor-agnostic method that does not rely on identifying specific surface antigens on cancer cells. Instead, it employs a modular amphiphile-ligand conjugate that can be administered intratumorally to "paint" tumor cells with a specific tag, enabling them to be recognized and destroyed by engineered CAR T cells.

Technical specifications
  • Mechanism: The therapy utilizes a phospholipid-polymer conjugate (amphiphile) linked to a small molecule ligand, such as fluorescein isothiocyanate (FITC).
  • Delivery: The amphiphile-ligand is administered via intratumoral injection, where it inserts its lipid tail into the plasma membrane of tumor cells, displaying the ligand on the cell surface.
  • Targeting: CAR T cells are engineered to specifically recognize the displayed ligand, triggering activation, proliferation, and tumor cell killing.
  • Systemic Immunity: Beyond direct tumor destruction, the therapy promotes the release of tumor antigens, which activates dendritic cells and primes endogenous, tumor-specific T cells. This process can induce systemic antitumor immunity, providing protection against distal, untreated tumors and preventing tumor rechallenge.
  • Modularity: While FITC was used as a model antigen, the system is modular and can be adapted to use various other ligands, including proteins, peptides, or other small molecules.
Technology readiness level

The technology is at a TRL of 3. It has been validated through preclinical studies in syngeneic and human tumor xenograft mouse models, demonstrating tumor regression and...

Generated Oct 4, 2026. Please verify key information.

About University of Pennsylvania

The University of Pennsylvania is a private, comprehensive research university with a large, interdisciplinary research enterprise on an urban campus in Philadelphia. For industry, the university combines an integrated academic health system with a research and technology park featuring co‑located labs, pilot and prototyping spaces, and access to shared instrumentation. Dedicated corporate engagement and technology transfer teams streamline sponsored research, IP, and startup formation, with incubator and venture resources to accelerate commercialization. Faculty attract substantial competitive federal funding from agencies such as the National Institutes of Health, National Science Foundation, Department of Energy, and the Department of Defense.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.